Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis (DEVOTE)

Biocon

Status and phase

Completed

Phase 3

Conditions

Postmenopausal Women With Osteoporosis

Treatments

Biological: Bmab 1000

Biological: Prolia®

Study type

Interventional

Funder types

Industry

Identifiers

NCT05345691

B1000-PMO-03-G-02

Details and patient eligibility

About

This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with osteoporosis

Full description

The study will consist of 3 study periods: Screening period; Part 1, double-blind active-controlled period; and Part 2, transition period. In the double-blind active-controlled period, eligible Patients will be randomized in a 1:1 ratio to receive either Bmab 1000 or Prolia®. Prior to dosing At Week 52, patients in Prolia® treatment group will be randomized again in a 1:1 ratio to either continue on Prolia® or be transitioned to Bmab 1000. To maintain the study blinding, the patients in the original Bmab 1000 arm will also go through the re-randomization procedure; however, they will continue to receive Bmab 1000. The interventions (Bmab 1000 or Prolia®) will be administered subcutaneously every 6 months. End-of-study visit will be at Week 78 post randomization (Month 18).

Enrollment

480 patients

Sex

Female

Ages

55 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Postmenopausal women, aged ≥55 and <80 years at screening. Postmenopausal is defined as 12 months of spontaneous amenorrhea with serum FSH (follicle-stimulating hormone) levels ≥40 mIU/mL at screening or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
Evidence of osteoporosis as assessed by lumbar spine (L1-L4) absolute BMD corresponding to a T-score classification ≤-2.5 and ≥-4.0.
At least 3 vertebrae in the L1-L4 region and at least one hip joint are evaluable by DXA at screening.
Patients with body weight ≥50 to <90 kg at screening.

Exclusion criteria

Patients with T-score of <-4.0 at the lumbar spine, total hip, or femoral neck.
Known history of previous exposure to denosumab (Prolia®, Xgeva®, or any biosimilar denosumab).
For prior or ongoing use of any osteoporosis treatment (other than calcium and vitamin D supplements) following points to be considered for the washout periods prior to the screening visit:

a. Oral bisphosphonate i. Ineligible if used for 3 or more years cumulatively ii. If used for <3 years, a gap of at least 1 year since the last dose is required at the screening visit b. Dose received any time
Systemic glucocorticosteroids
Patients with ongoing serious infections
Evidence of any of the following per the patient's history, DXA, or X-ray review and/or current disease:
1. Patient in bed rest for 2 or more weeks during the last 3 months prior to screening
2. Current hyperthyroidism or hypothyroidism
3. History and/or current hyperparathyroidism or hypoparathyroidism
4. Current hypocalcemia or hypercalcemia based on albumin-adjusted serum calcium
5. Any bone disease including bone metastasis or metabolic disease (except for osteoporosis), eg, osteomalacia or osteogenesis imperfecta, rheumatoid arthritis, Paget's disease, ALP (alkaline phosphatase) elevation (at investigator's discretion), Cushing's disease, clinically significant hyperprolactinemia (at investigator's discretion), fibrous dysplasia, malabsorption syndrome which may interfere with the interpretation of the results
6. History and/or presence of one severe or 3 or more moderate vertebral fractures
7. History and/or presence of hip fracture or bilateral hip replacement
8. Presence of an active healing fracture according to assessment of investigator
9. History of severe skeletal pain with bisphosphonates which, as per the investigator, is a risk to her participation in the trial
10. Oral/dental or periodontal conditions: